Skip to main content
. 2022 Jan 31;12(9):1191–1195. doi: 10.1002/alr.22964

FIGURE 1.

FIGURE 1

Scatterplots of the relationship between change from baseline in nasal polyp score (NPS) and change in (A) nasal interleukin (IL)‐5 at week 24 in SINUS‐52 (Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps), and (B) serum total IgE and (C) urinary leukotriene E4 (LTE4) at week 52 in SINUS‐52 (observed values; intent‐to‐treat [ITT] population). n indicates the number of patients with available data for biomarker assessment; and q2w, every 2 weeks.